K. Vandormael

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

H. A. P. Pols, Dieter Felsenberg, David A. Hanley et al. · Osteoporosis International · 1999 · 594 citations

Bone Disease, Bone Health, Low Bone Mass +8

Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal‐salt diet

Jules I. Schwartz, K. Vandormael, Marie-Pierre Malice et al. · Clinical Pharmacology & Therapeutics · 2002 · 158 citations

Nutrition, Elderly Subjects, Mm Hg +21

Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study

Michel Farnier, Maurizio Averna, Luc Missault et al. · International Journal of Clinical Practice · 2009 · 68 citations · Full text

The Effect of Alendronate on Bone Mass After Distal Forearm Fracture

Éric Clément, P. Patka, K. Vandormael et al. · Journal of Bone and Mineral Research · 2000 · 64 citations · Full text

Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease

Vivencio Barrios, Nicolas Amabile, Franck Paganelli et al. · International Journal of Clinical Practice · 2005 · 46 citations